IO Biotech, Inc. — Director's Dealing 2022

Oct 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2022-10-17

Reporting Person: Sullivan Amy (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-17	Stock Option (Right to Buy)	$2.55	A	288152	Acquired	2032-10-17	Common Stock (288152)	Direct

Footnotes

F1: One-fourth of these options vest on 10/15/2023, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control.